CTOs on the Move


 
Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pieris.com
  • 255 State Street 9th floor
    Boston, MA USA 02109
  • Phone: 857.246.8998

Executives

Name Title Contact Details

Funding

Pieris raised $50.6M on 02/20/2018
Pieris raised $32M on 11/10/2019
Pieris raised $17.3M on 06/25/2021
Pieris raised $25M on 07/05/2021

Similar Companies

HBP

Hudson Botanical Processing is a full-service cannabis manufacturing company serving the operational needs of the cannabis industry. They work with industry-leading cannabis brands to produce and distribute the highest quality products in Massachusetts.

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Asembia

Asembia constantly connects and strengthens the pharmaceutical industry to improve the experiences of patients everywhere.

Jim's Pharmacy and Gifts

Jim's Pharmacy and Gifts is a Port Angeles, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.